Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:42:14.400Z.
Calculation as of: 2026-10-06T13:42:14.400Z.
Quote observation: 2026-10-06T13:38:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26b9d76e1867df839f3ea79fd47ae1c5236575fa33f8c6240ddbf9d3395e1dfe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$36.70M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$38.38M
Price/FCF Ratio
N/A
TTM Avg
8.40
3Y Avg
37.30
5Y Avg
47.13
Market Cap
$39.48M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.61M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $37.59M | N/A | 8.65 | 28.12 | 30.77 |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.70M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.38M | N/A | 8.40 | 37.30 | 47.13 |
| Edesa Biotech, Inc. (EDSA)vs › | $38.53M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $37.40M | N/A | 2.50 | 3.99 | 20.14 |
| Elutia Inc (ELUT)vs › | $34.93M | N/A | N/A | N/A | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $39.48M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.18M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
